It has become customary that a session is held at the British Association of Urological Surgeons (BAUS) annual meeting, wherein the most important advances in the major urological sub-specialities are summarised by British opinion leaders for the benefit of the core of urologists. It gives us pleasure to present in this paper the topics covered at the BAUS meeting in June 2015, in Manchester, UK.
FelettoEBangACole-ClarkD. An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high?World J Urol2015; 33(11): 1677–1687.
2.
SchroderFHHugossonJRoobolMJ. Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet2014; 384: 2027–2035.
3.
BuzzoniCAuvinenARoobolMJ. Metastatic prostate cancer incidence and prostate-specific antigen testing: New insights from the European Randomized Study of Screening for Prostate Cancer. Eur Urol2015; 68: 885–890.
4.
HamoenEHDe RooijMWitjesJA. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: A diagnostic meta-analysis. Eur Urol2015; 67: 1112–1121.
PanebiancoVBarchettiFSciarraA. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: A randomized study. Urol Oncol2015; 33: 17, e1–7.
7.
SiddiquiMMRais-BahramiSTurkbeyB. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. J Am Med Ass2015; 313: 390–397.
8.
WysockJSRosenkrantzABHuangWC. A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: The PROFUS trial. Eur Urol2014; 66: 343–351.
9.
National Institute for Care and Clinical Excellence (NICE). Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (DG17), https://www.nice.org.uk/guidance/dg17 (2015, accessed 10 August 2015).
10.
PorpigliaFRussoFManfrediM. The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy?J Urol2014; 192: 60–66.
11.
KlotzLVespriniDSethukavalanP. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol2015; 33: 272–277.
12.
MusunuruHBMKlotzLVespiriniD. Cautionary tale of active surveillance in intermediate-risk patients: Overall and cause-specific survival in the Sunnybrook experience. J Clin Oncol2015; 33: S7. Abstract 163.
13.
RamsayCRAdewuyiTEGrayJ. Ablative therapy for people with localised prostate cancer: A systematic review and economic evaluation. Health Technol Assess2015; 19: 1–490.
14.
JamesNSydesMRMasonMD, STAMPEDE group. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476) 2015 ASCO Annual Meeting. J Clin Oncol2015; 33: Sl. Abstract 5001.
15.
KellyJMaynardLMostafidA. Celecoxib for the treatment of non-muscle invasive bladder cancer (NMIBC): Results of the randomized BOXIT trial (CRUK/07/004). Brit J Urol Int2015; 115: S7–S11.
16.
KellyJBuckleyLDevallAJ. HYMN: A randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of BCG or institutional standard in patients with recurrence of non-muscle invasive bladder cancer (NMIBC) following induction or maintenance BCG therapy. Brit J Urol Int2015; 115: S7–S12.
17.
ArendsTJHNativOMaffezziniM. Results of the first randomised controlled trial comparing intravesical radiofrequency induced chemohyperthermia with mitomycin-C versus BCG for adjuvant treatment of patients with intermediate and high-risk non-muscle invasive bladder cancer. Eur Urol Supplements2015; 14: e944–e944a.
18.
BochnerBHDalbagniGSjobergDD. Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: A randomized clinical trial. Eur Urol2015; 67: 1042–1050.
19.
SimoneGDe NunzioCSperdutiI. Trends in the use of partial nephrectomy for cT1 renal tumours: Analysis of a 10-yr European multicenter dataset. Eur Urol2015; 2: S14.
20.
GoASChertowGMFanD. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med2004; 351: 1296–1305.
21.
CapitanioUTerroneCAntonelliA. Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a–T1b renal mass and normal preoperative renal function. Eur Urol2015; 67: 683–689.
22.
TomaszewskiJJKutikovA. Retrospective comparison of cardiovascular risk in preselected patients undergoing kidney cancer surgery: Reflection of reality or simply what we want to hear?Eur Urol2015; 67: 690–691.
23.
MensahEEHounsomeLHVerneJV. Cardiovascular outcomes in kidney cancer patients. Brit J Urol Int2015; 115: S47–S48.
24.
VolkovaMISkvortcovIKlimovAV. Partial nephrectomy does not improve cardio-specific survival in patients with localized renal cell carcinoma. Eur Urol2015; 2: S14.
25.
DemirjianSLaneBDerweeshI. Extended follow-up of chronic kidney disease due to surgical removal of nephrons: Impact on survival and functional stability. In: AUA Annual Meeting, New Orleans, LA, USA, 15 May–19 May 2015, poster no. PD29–09.
26.
GorRUzzoRLiT. Surgical chronic kidney disease appears to be a distinct subtype of chronic kidney disease based on mortality risks following renal surgery In: AUA Annual Meeting, New Orleans, LA, USA, 15 May–19 May 2015, poster no. PD49–11.
27.
HaasNBManolaJUzzoRG. Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN Phase III trial. J Clin Oncol2015; 33(Suppl 15): 4508.
28.
BlinmanPLDavisIDMartinA. Patients’ preferences for adjuvant sorafenib after resection of intermediate or high-risk renal cell carcinoma in the SORCE trial: What makes it worthwhile?J Clin Oncol2015; 33(Suppl 7): 415.
29.
ThomasAZAdibiMBorregalesL. Surgical management for local retroperitoneal recurrence after radical nephrectomy in the targeted therapy era. J Clin Oncol2015; 33: S7.
30.
PsutkaSHeidenreichMBoorjianS. Evaluation and management of renal fossa recurrence following nephrectomy for renal cell carcinoma. In: AUA Annual Meeting, New Orleans, LA, USA, 15 May–19 May 2015, poster no. PD35–07.
31.
ShahAYCampbellMTNautiyalKD. Long-term survivorship in patients with metastatic renal cell cancer (mRCC) managed with metastasectomy: A retrospective study from the MD Anderson Cancer Center (MDACC). J Clin Oncol2015; 33: S7.
32.
FukudaHKondoTOmaeK. The clinical benefit of metastasectomy in metastatic renal cell carcinoma in the era of targeted molecular therapy. In: AUA Annual Meeting, New Orleans, LA, USA, 15 May–19 May 2015, poster no. MP69–09.
33.
RussellCSpiessPEKassoufW. Surgical Resection of Isolated Retroperitoneal Lymph Node Recurrence of RCC: Results From A Multi-Institutional International Cohort. Russell AUA2015. In: AUA Annual Meeting, New Orleans, LA, USA, 15 May–19 May 2015, poster no. MP59–20.
National Institute for Care and Clinical Excellence (NICE). The TURis system for transurethral resection of the prostate, https://www.nice.org.uk/guidance/mtg23.
AbramsPKelleherCStaskinD. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Efficacy and safety results from a randomised, double-blind, dose-ranging, Phase 2 study (Symphony). Eur Urol2015; 67: 577–588.
GelbardMGoldsteinIWaineJ. Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie’s disease in two large randomized, placebo-controlled Phase 3 trials. J Urol2013; 190: 199–207.
42.
SilvaLAAndrioloRBAtallahAN. Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery. Cochrane Database Syst Rev2014; CD008306.
KamphuisGMBaardJWestendarpM. Lessons learned from the CROES percutaneous nephrolithotomy global study. World J Urol2015; 33: 223–233.
48.
SkolarikosAGrossAJKrebsA. Outcomes of flexible ureterorenoscopy for solitary renal stones in the CROES URS global study. J Urol2015; 194: 137–143.
49.
TraxerOThomasA. Prospective evaluation and classification of ureteral wall injuries…from insertion of a ureteral access sheath during RIRS. J Urol2013; 189: 580–584.
50.
TorricelliFCDeSHinckB. Flexible ureteroscopy with a ureteral access sheath: When to stent?Urology2014; 83: 278–281.
51.
NabiGCookJN’DowJ. Outcomes of stenting after uncomplicated URS: Systematic review and meta-analysis. Brit Med J2007; 334: 572.
52.
PengfeiSYutaoLJieY. The results of ureteral stenting after ureteroscopic lithotripsy for ureteral calculi: Systematic review and meta-analysis. J Urol2011; 186: 1904–1909.
53.
Perez CastroEOstherPJJingaV. Differences in ureteroscopic stone treatment and outcomes for distal, mid-, proximal, or multiple ureteral locations: The CROES ureteroscopy global study. Eur Urol2014; 66: 102–109.
54.
GeorgescuDMulţescuRGeavleteB. Intraoperative complications after 8150 semirigid ureteroscopies for ureteral lithiasis: Risk analysis and management. Chirurgia2014; 109: 369–374.
55.
BarnesKTBingMTTracyCR. Do ureteric stent extraction strings affect quality of life or complications after URS for urolithiasis: A prospective RCT. Brit J Urol Int2014; 113: 605–609.
56.
TranTYMcGillenKConeEB. Triple D Score is a reportable predictor of shockwave lithotripsy stone-free rates. J Endourol2015; 29: 226–230.
57.
PickardRStarrKMacLennanG. Medical expulsive therapy in adults with ureteric colic: A multicentre, randomised, placebo-controlled trial. Lancet2015; 386: 341–349.
